Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−48.13 M EUR
173.23 K EUR
62.81 M
About InflaRx N.V.
Sector
Industry
CEO
Niels Christoph Riedemann
Website
Headquarters
Jena
Founded
2007
ISIN
NL0012661870
FIGI
BBG00J7RXCT7
InflaRx NV is a clinical-stage biopharmaceutical company, which engages in the discovery and development of inhibitors of the complement activation factor known as C5a and its receptor C5aR. Its primary product candidate is Vilobelimab. The company was founded by Niels Christoph Riedemann, Renfeng Guo, and Nicolas Fulpius in December 2007 and is headquartered in Jena, Germany.
Related stocks
IFRX 1D Continuedtest
Just having some fun after a great ski trip to Breckenridge, Co for a couple of weeks. Let's get back into it.
InflaRx NV is a clinical-stage biopharmaceutical company, which engages in the discovery and development of inhibitors of the complement activation factor known as C5a. Its products
InflaRx recovering temporarily. IFRXWe are not in the business of getting every prediction right, no one ever does and that is not the aim of the game. The Fibonacci targets are highlighted in green with invalidation in red. Fibonacci goals, it is prudent to suggest, are nothing more than mere fractally evident and therefore statistic
IFRX 1D Swing Editiontest
InflaRx NV is a clinical-stage biopharmaceutical company, which engages in the discovery and development of inhibitors of the complement activation factor known as C5a. Its products include IFX-1 and IFX-2. The company was founded by Niels Christoph Riedemann, Renfeng Guo and Nicolas Fulpius in
InflaRx Announces Positive Data from Third Cohort of Phase IIa OIFRX: InflaRx N.V.
2021-10-27 07:30:00
InflaRx Announces Positive Data from Third Cohort of Phase IIa Open-Label Study with Vilobelimab in Pyoderma Gangraenosum
$IFRX Strong Close!Keeping this one on watch most likely looking for the same volume coming in Monday. We closed very strong on Friday Which typically means we are looking for a strong move to the upside on Monday... Also looking for that SweetSpot break at $2.85 for Entry Confirmation.
$IFRX is gonna fall todayPupm&Dump trading strategy idea.
$IFRX is rising too much today.
The demand for shares of the company looks lower than the supply.
This and other conditions can cause a fall in the share price today.
So I opened a short position from $3,21;
stop-loss — $3,35;
take-profit — $2,93/MOC
Do not view
IFRX Technical Analysis 🧙InflaRx NV is a clinical-stage biopharmaceutical company that is focused on applying proprietary anti-C5a technology to discover and develop specific inhibitors of the complement activation factor known as C5a. The lead product candidate of the company is IFX-1, which is developed for the treatment
LONG // IFRX // US STOCKSTrade Safe! Don`t be greedy!
Take care and place small trades! If necessary, I will place more long trades at this asset!
In my opinion, this stock is at a good opportunity and has good potential for the stock price to go up!
$IFRX can rise in the next daysContextual immersion trading strategy idea.
InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology primarily in the United States and Europe.
The share price rose after good earnings. I see some preconditions the share price will continue g
See all ideas
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
Depending on the exchange, the stock ticker may vary. For instance, on SWB exchange InflaRx N.V. stocks are traded under the ticker IF0.
We've gathered analysts' opinions on InflaRx N.V. future price: according to them, IF0 price has a max estimate of 8.60 EUR and a min estimate of 1.72 EUR. Watch IF0 chart and read a more detailed InflaRx N.V. stock forecast: see what analysts think of InflaRx N.V. and suggest that you do with its stocks.
Yes, you can track InflaRx N.V. financials in yearly and quarterly reports right on TradingView.
InflaRx N.V. is going to release the next earnings report on Oct 30, 2025. Keep track of upcoming events with our Earnings Calendar.
IF0 earnings for the last quarter are −0.21 EUR per share, whereas the estimation was −0.21 EUR resulting in a 0.00% surprise. The estimated earnings for the next quarter are −0.15 EUR per share. See more details about InflaRx N.V. earnings.
InflaRx N.V. revenue for the last quarter amounts to 39.43 K EUR, despite the estimated figure of 39.43 K EUR. In the next quarter, revenue is expected to reach 69.14 K EUR.
IF0 net income for the last quarter is −13.88 M EUR, while the quarter before that showed −8.09 M EUR of net income which accounts for −71.63% change. Track more InflaRx N.V. financial stats to get the full picture.
No, IF0 doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Sep 21, 2025, the company has 74 employees. See our rating of the largest employees — is InflaRx N.V. on this list?
Like other stocks, IF0 shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade InflaRx N.V. stock right from TradingView charts — choose your broker and connect to your account.